[New drug approval: Pembrolizumab - Neoadjuvant/adjuvant treatment for localized high-risk triple negative breast cancer].
| Autor: | Minot-This MS; Institut Gustave Roussy, département d'oncologie médicale, comité sénologie, Villejuif, France. Electronic address: ms.minot@gmail.com., Deleuze A; Centre Eugène Marquis, département d'oncologie médicale, Rennes, France. |
|---|---|
| Jazyk: | francouzština |
| Zdroj: | Bulletin du cancer [Bull Cancer] 2022 Oct; Vol. 109 (10), pp. 988-989. Date of Electronic Publication: 2022 Jul 22. |
| DOI: | 10.1016/j.bulcan.2022.06.006 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|